Document Detail

A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes.
MedLine Citation:
PMID:  6362387     Owner:  NLM     Status:  MEDLINE    
The effectiveness of oral propafenone was evaluated for the treatment of ventricular premature complexes (VPCs) in 12 patients, using a single-blind, dose-ranging trial followed by a double-blind comparison with placebo, and then an open-label, long-term protocol. During dose ranging, 8 of 12 patients achieved greater than or equal to 80% suppression of total VPCs (mean 83%) (p less than 0.01 vs single-blind placebo). Paired VPCs were suppressed greater than or equal to 90% and ventricular tachycardia was eliminated in 11 of the 12 patients (p less than 0.01). The effectiveness of propafenone for treatment of VPCs was confirmed during the double-blind trial (p less than 0.05 vs double-blind placebo) and during treatment for 6 months (p less than 0.05 vs initial single-blind placebo). Propafenone prolonged the PR interval by 16% (p less than 0.01 vs single-blind placebo) and the QRS interval by 18% (p less than 0.001). Left ventricular systolic performance decreased as assessed by 2-dimensional echocardiography (p less than 0.01 vs single-blind placebo). Propafenone increased serum digoxin levels in 5 of 5 patients (mean increase of 83%). Side effects included exacerbation of congestive heart failure (1 patient) and conduction abnormalities (2 patients). Thus, propafenone is effective for treatment of total and repetitive VPCs. Although generally well tolerated, the drug reduces left ventricular systolic function and atrioventricular conduction and increases serum digoxin levels.
D M Salerno; G Granrud; P Sharkey; R Asinger; M Hodges
Related Documents :
8311367 - Managing chronic atrial fibrillation: a markov decision analysis comparing warfarin, qu...
2220637 - Electrocardiographic signal-averaging during atrial pacing and effect of cycle length o...
11216977 - Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatmen...
6541867 - Effect of amiodarone on left ventricular ejection and filling in hypertrophic cardiomyo...
18714577 - Two rare cases of methotrexate-induced pneumonitis and pleurisy in patients with gestat...
6853747 - Mexiletine in the treatment of recurrent ventricular tachycardia. prediction of long-te...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  53     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1984 Jan 
Date Detail:
Created Date:  1984-02-14     Completed Date:  1984-02-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  77-83     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Arrhythmias, Cardiac / diagnosis,  drug therapy*
Clinical Trials as Topic
Double-Blind Method
Heart Rate
Heart Ventricles
Middle Aged
Propiophenones / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Propiophenones; 54063-53-5/Propafenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlle...
Next Document:  Efficacy of mexiletine in chronic ventricular arrhythmias compared with quinidine: a single-blind, r...